Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 1, 2017, Pages 229-236

  Hajarizadeh, Behzad ^a   Grebely, Jason ^a   McManus, Hamish ^a   Estes, Chris ^b   Razavi, Homie ^b   Gray, Richard T ^a   Alavi, Maryam ^a   Amin, Janaki ^a   McGregor, Skye ^a   Sievert, William ^c   Thompson, Alexander ^d   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Center for Disease Analysis   (United States)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

diagnosis; epidemiology; HCV infection; liver fibrosis; liver transplantation; public health; treatment

Indexed keywords

BOCEPREVIR; INTERFERON; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; CHRONIC HEPATITIS C; HUMAN; LIVER FIBROSIS; LIVER GRAFT; MAJOR CLINICAL STUDY; PATIENT CARE; PRIORITY JOURNAL; COST OF ILLNESS; ECONOMICS; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; AUSTRALIA; COST OF ILLNESS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS;

EID: 85008517651     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13453     Document Type: Article

References (50)

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 553–562.
2. Sievert W, Razavi H, Estes C et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J. Gastroenterol. Hepatol. 2014; 29: 1–9.
3. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2015. Australia: The Kirby Institute, UNSW Australia, Sydney NSW 2052, 2015.
4. Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of perfectovir. Clin. Infect. Dis. 2015; 60: 1829–1836.
5. Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat. Rev. Gastroenterol. Hepatol. 2015; 12: 284–292.
6. Razavi H, Waked I, Sarrazin C et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J. Viral Hepat. 2014; 21: 34–59.
7. Australian Institute of Health and Welfare. National drug strategy household survey (NDSHS), 1995–2014. Available from URL: http://www.aihw.gov.au/alcohol-and-other-drugs/ndshs/ (Accessed last 20 February 2016).
8. Iversen J, Maher L. Australia NSP Survey, 20 years national data report: Prevalence of HIV, HCV and injecting and sexual behaviour among Needle and Syringe Program attendees. Sydney: The Kirby Institute, UNSW Australia; 2015.
9. Bryant J, Paquette D, Wilson H. Syringe coverage in an australian setting: does a high level of syringe coverage moderate syringe sharing behaviour? AIDS Behav. 2012; 16: 1156–1163.
10. Razali K, Thein HH, Bell J et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007; 91: 228–235.
11. Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex. Transm. Infect. 2006; 82: iii56–iii63.
12. Centers for Disease Control and Prevention. Recommendations for follow-up of health-care workers after occupational exposure to hepatitis C virus. MMWR Morbidity and Mortality Weekly Report 1997; 46: 603–606.
13. Hasan F, Askar H, Al Khalidi J, Al Shamali M, Al Kalaoui M, Al Nakib B. Lack of transmission of hepatitis C virus following needlestick accidents. Hepatogastroenterology 1999; 46: 1678–1681.
14. Hauri AM, Armstrong GL, Hutin YJF. The global burden of disease attributable to contaminated injections given in health care settings. Int. J. STD AIDS 2004; 15: 7–16.
15. Hutin YJF, Hauri AM, Armstrong GL. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. BMJ 2003; 327: 1075.
16. Grebely J, Page K, Sacks-Davis R et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014; 59: 109–120.
17. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J. Viral Hepat. 2006; 13: 34–41.
18. University of California Berkeley, Max Planck Institute for Demographic Research. The human mortality database. Available from URL: http://www.mortality.org (Accessed last 20 February 2016).
19. Kamper-Jørgensen M, Ahlgren M, Rostgaard K et al. Survival after blood transfusion. Transfusion 2008; 48: 2577–2584.
20. Engstrom A, Adamsson C, Allebeck P, Rydberg U. Mortality in patients with substance abuse: a follow-up in Stockholm County, 1973–1984. Int. J. Addict. 1991; 26: 91–106.
21. Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction 1994; 89: 1299–1308.
22. Hickman M, Carnwath Z, Madden P et al. Drug-related mortality and fatal overdose risk: Pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J. Urban Health 2003; 80: 274–287.
23. Perucci CA, Davoli M, Rapiti E, Abeni DD, Forastiere F. Mortality of intravenous drug users in Rome: a cohort study. Am. J. Public Health 1991; 81: 1307–1310.
24. Frischer M, Goldberg D, Rahman M, Berney LEE. Mortality and survival among a cohort of drug injectors in Glasgow, 1982–1994. Addiction 1997; 92: 419–427.
25. Bjornaas MA, Bekken AS, Ojlert A et al. A 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo. BMC Psychiatry 2008; 8: 8.
26. Roberts SK, Weltman MD, Crawford DHG et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial. Hepatology 2009; 50: 1045–1055.
27. Gidding HF, Law MG, Amin J et al. Hepatitis C treatment outcomes in Australian clinics. Med. J. Aust. 2012; 196: 633–637.
28. Bernfort L, Sennfalt K, Reichard O. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand. J. Infect. Dis. 2006; 38: 497–505.
29. Gloeckler-Ries LA, Young JL, Keel GE et al. SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988–2001, patient and tumor characteristics. Bethesda, MD: National Cancer Institute,SEER Program, 2007.
30. Iversen J, Grebely J, Topp L, Wand H, Dore G, Maher L. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011. J. Viral Hepat. 2014; 21: 198–207.
31. Hatzakis A, Chulanov V, Gadano AC et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2. J. Viral Hepat. 2015; 22: 26–45.
32. Sibley A, Han KH, Abourached A et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm – volume 3. J. Viral Hepat. 2015; 22: 21–41.
33. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Geneva, Switzerland: World Health Organization, 2016.
34. Australian Government Department of Health and Ageing. Fourth National Hepatitis C Strategy 2014–2017: Commonwealth of Australia, 2014. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-hepc (Accessed last 20 February 2016)
35. Grebely J, Bryant J, Hull P et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J. Viral Hepatitis 2011; 18: e104–e116.
36. Stoové MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend. 2005; 77: 81–86.
37. Grebely J, Alavi M, Micallef M et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study. Addiction 2015; 111: 311–319.
38. Wade AJ, Macdonald DM, Doyle JS et al. The cascade of care for an australian community-based hepatitis C treatment service. PLoS One 2015; 10 (11e0142770).
39. Alavi M, Law MG, Grebely J et al. Lower life expectancy among people with an HCV notification: a population-based linkage study. J. Viral Hepat. 2014; 21: e10–e18.
40. Gidding H, Dore G, Amin J, Law M. Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study. BMC Public Health 2011; 11: 52.
41. Curry MP, O'Leary JG, Bzowej N et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N. Engl. J. Med. 2015; 373: 2618–2628.
42. NNDSS Annual Report Working Group. 2014 Australia's notifiable diseases status. 2014: Anual report of National Notifiable Diseases Surveillance System Communicable diseases intelligence, 2016; 40: E48–E145.
43. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998; 339: 1485–1492.
44. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–1432.
45. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
46. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975–982.
47. Poordad F, McCone J, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195–1206.
48. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405–2416.
49. Fried MW, Buti M, Dore GJ et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. Hepatology 2013; 58: 1918–1929.
50. Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403–413.